Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma

XiaoChang Fang,Lin Shu,TianLiang Chen,XiaoLe Zhao,LiuCui Yang,Tingting Dou,Lijie Yang,Xuanfei Li,Maohui Feng

DOI: https://doi.org/10.1186/s12943-023-01901-z

IF: 37.3

2024-01-12

Molecular Cancer

Abstract:Malignant peritoneal mesothelioma (MPM) is an extremely rare and highly invasive tumor. Due to the lack of accurate models that reflect the biological characteristics of primary tumors, studying MPM remains challenging and is associated with an exceedingly unfavorable prognosis. This study was aimed to establish a new potential preclinical model for MPM using patient-derived MPM organoids (MPMOs) and to comprehensively evaluate the practicality of this model in medical research and its feasibility in guiding individualized patient treatment.

oncology,biochemistry & molecular biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the challenges faced by the research and treatment of Malignant Peritoneal Mesothelioma (MPM). Due to the lack of models that can accurately reflect the biological characteristics of the primary tumor, research on MPM has been difficult, and the prognosis of patients is extremely poor. Therefore, this article aims to establish a new potential pre - clinical model - patient - derived MPM organoids (MPMOs), and comprehensively evaluate the practicality of this model in medical research and the feasibility of guiding personalized treatment.

Specifically, researchers construct MPMOs by obtaining tumor tissues from MPM patients and use these organoids to conduct research in the following aspects:
1. **Replication of genetic and histological features**: Through histopathological analysis and whole - genome sequencing (WGS), determine whether MPMOs can accurately replicate the genetic and histological characteristics of the primary tumor.
2. **Establishment of in - vivo models**: Use MPMOs to establish subcutaneous and orthotopic xenograft models and evaluate their feasibility as in - vivo MPM models.
3. **Drug screening**: Use MPMOs for drug sensitivity testing and compare with the results of retrospective analysis after patient treatment to evaluate the potential of MPMOs to predict the drug efficacy of MPM patients.

In conclusion, this study aims to provide a new tool, which not only helps to promote basic research on MPM, but also provides support for the formulation of personalized treatment strategies.